Today's Rundown AstraZeneca's Tagrisso, headed for big sales boost, cuts lung cancer recurrence by 83% Allogene reports 63% response rate in early trial of off-the-shelf CAR-T in lymphoma Pfizer, Merck KGaA's Bavencio lines up for bladder cancer edge with survival win Merck's Keytruda doubles time to disease progression in certain colorectal cancer patients Has AstraZeneca finally found a place for long-plagued I-O candidate tremelimumab? GSK's anti-BCMA antibody gets a data boost ahead of FDA decision In stomach cancer, AstraZeneca and Daiichi's Enhertu goes where Roche's Kadcyla couldn't Myovant details speedy effects of prostate cancer med relugolix Gilead CAR-T med Yescarta delivers 93% response rate in slow-growing lymphoma Ziopharm's IL-12 gene therapy boosts survival in hard-to-treat brain cancer Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data Why 'hot' kidney tumors don't respond to immunotherapy with PD-1 blockers Pfizer, Merck KGaA's Bavencio posts win in rare gynecological cancer Featured Story | | | Thursday, May 28, 2020 In mid-April, at the recommendation of an independent data monitoring committee, AstraZeneca unblinded a phase 3 trial of Tagrisso two years early. Now, the public is getting a look at what prompted the move: results from a study investigators are calling “a home run.” |
|
|---|
|
Top Stories Friday, May 29, 2020 Allogene released expanded data from a phase 1 trial of its off-the-shelf, CD19-directed CAR-T, ALLO-501, plus its antibody ALLO-647. The response rate wasn't quite as impressive as what the company reported two weeks ago, but the details could generate some excitement among Wall Street analysts. Thursday, May 28, 2020 In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data in post-chemo patients. In a phase 3 study, Bavencio extended patients’ lives by a median 21.4 months, compared with 14.3 months for best supportive care. Thursday, May 28, 2020 The results are out, and they’re practice-changing: Merck’s Keytruda can double the time to disease worsening in patients with certain types of colorectal cancer. And the checkpoint inhibitor not only kept cancer away longer, but also in a larger proportion of patients. Sunday, May 31, 2020 AstraZeneca’s CTLA4 candidate tremelimumab has suffered a host of clinical failures that have so far kept it off the market. But new phase 2 results show the company might just be able to use the drug in a new way. Wednesday, May 27, 2020 Last December, GlaxoSmithKline’s BCMA-targeting medicine shrank tumors in one-third of patients with advanced multiple myeloma, teeing up an FDA submission. Now, the antibody-drug conjugate is padding its case as the British drugmaker awaits the agency’s decision. The treatment's response rates stayed steady and it extended patients' lives by 15 months. Friday, May 29, 2020 Daiichi Sankyo and AstraZeneca’s Enhertu previously wowed industry watchers with stellar clinical data in heavily pretreated breast cancer. Now, the antibody-drug conjugate can brag about being the first HER2 drug to extend patients lives in previously-treated gastric cancer. Friday, May 29, 2020 Myovant Sciences revealed last fall that its prostate cancer drug beat the standard of care at lowering patients’ testosterone levels. Now, it's laying out details, including how quickly the drug worked and how low it brought testosterone levels as well as how the drug affected heart problems in the patient group. Friday, May 29, 2020 Gilead Sciences is working to move CAR-T therapy Yescarta into other types of non-Hodgkin lymphoma, and if data from an interim trial look-in are any indication, it’s well on its way. In patients who'd relapsed or proven treatment-resistant, Yescarta spurred a benefit in 93% and cleared cancer completely in 80%, interim study data show. Friday, May 29, 2020 Radiation, chemotherapy and surgery don’t cut it against glioblastoma, an aggressive type of brain cancer that often recurs with a vengeance. Ziopharm is working on a “remote-controlled” gene therapy to buy these patients more time—and early data show it extended patients’ lives by more than a year. Sunday, May 31, 2020 Roche may have just grabbed the first FDA nod for a checkpoint inhibitor in previously untreated liver cancer, but Merck & Co. is hoping it won’t be far behind. In data presented at ASCO, its immuno-oncology star Keytruda paired with Lenvima spurred a response in 36% of first-line liver cancer patients. Friday, May 29, 2020 It’s reasonable to assume PD-1 inhibitors like Bristol Myers Squibb's Opdivo, which unleash the body’s own immune system to target and destroy cancer, work best in “hot” tumors that are flooded with immune cells. But a new study by scientists at the Dana-Farber Cancer Institute found that is not the case in kidney cancer. Thursday, May 28, 2020 Pfizer and Merck KGaA’s Bavencio is having itself an ASCO. In addition to putting up game-changing results in bladder cancer, it’s posted a win in a rare, chemo-resistant gynecological cancer, too. |
